Presence of protein could spare breast cancer patients unnecessary therapy, study suggests

Scientists and clinicians have identified a breast cancer protein which indicates whether a patient is likely to respond to a particular type of therapy.

Camera icon
NTU scientist, Dr Amanda Miles

The study – involving a team at Nottingham Trent University and Nottingham University Hospitals NHS Trust – could mean that in the UK alone thousands of women each year would be spared treatment from which they would not benefit.

The researchers found that women with ‘oestrogen receptor negative’ and ‘HER2 positive’ breast cancers responded well to the drug Herceptin (trastuzumab) if they expressed the ‘PRPF38B’ protein on the surface of their cancer cells.

This means that patients could be screened and recommended for this treatment should they express the protein in this location.

As well as reducing unnecessary treatment and possible side-effects, it would also mean a significant cost-saving for the NHS, the researchers say.

As part of the study, reported in the journal Oncotarget, expression of the protein was investigated in 1,650 tissue samples from patients, and its association with patient clinical outcomes was assessed.

It was found that women who expressed the protein on the surface of their breast cancer cells and who received Herceptin (trastuzumab) – which works by controlling the growth of cancer cells – were more likely to remain disease free.

In the UK alone, it is thought that about 4,500 breast cancer patients a year would benefit from screening before being prescribed the treatment.

“Proteins that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer,” said Dr Amanda Miles, a Senior Research Fellow in Nottingham Trent University’s John van Geest Cancer Research Centre.

She said: “Our study has revealed the potential of measuring this ‘membranous’ form of PRPF38B for predicting therapeutic response to Herceptin therapy in patients with these types of breast cancer.

“Being able to identify whether a patient would or would not benefit from a particular treatment will help to both reduce any unnecessary side-effects and save the NHS money.

“We’d like to explore this protein’s role as an indicator of response to Herceptin therapy in other types of cancer.”

It is the latest study involving the John van Geest Cancer Research Centre, the aim of which is to develop new approaches for improving the diagnosis, management and treatment of cancer, and thereby improve the quality of life and survival of patients with cancer.

Previous work has included paving the way to better understand how prostate cancer spreads around the body, identifying a breast cancer gene which indicated which patients will benefit from chemotherapy, and the development of a new vaccine to target the most deadly form of brain tumour.

  • Notes for editors

    Press enquiries please contact Dave Rogers, Head of Communications, on telephone +44 (0)115 848 8782, or via email; or Kirsty Green, Press and Public Affairs Manager, on telephone +44 (0)115 848 8799, or via email.

    • Nottingham Trent University is Modern University of the Year 2018. The Times and Sunday Times Good University Guide award recognises NTU for its strong student satisfaction, quality of teaching, overall student experience and engagement with employers.
    • Nottingham Trent University (NTU) has been awarded the highest, gold, rating in the Government’s Teaching Excellence Framework for its outstanding teaching and learning.
    • NTU is one of the largest UK universities with nearly 28,000 students and more than 3,500 staff across four campuses, contributing £496m to the UK economy every year. It is one of the most environmentally-friendly universities, containing some of the country’s most inspiring and efficient award-winning buildings.
    • The University is passionate about creating opportunities and its extensive outreach programme is designed to enable Nottingham Trent to be a vehicle for social mobility. NTU is the sixth biggest recruiter of students from disadvantaged backgrounds in the country and 95.6% of the its graduates go on to employment or further education within six months of leaving.
    • NTU is home to world-class research, winning The Queen’s Anniversary Prize in 2015 - the highest national honour for a UK university. It recognised the University’s pioneering projects to improve weapons and explosives detection in luggage, enable safer production of powdered infant formula and combat food fraud.
    • With an international student population of approximately 2,600 from around 100 countries, the University prides itself on its global outlook.

Presence of protein could spare breast cancer patients unnecessary therapy, study suggests

Published on 1 December 2017
  • Subject area: Sciences including sport sciences
  • Category: Press office; School of Science and Technology

Still need help?

+44 (0)115 941 8418